[HTML][HTML] Efficacy of rituximab versus tacrolimus in difficult-to-treat steroid-sensitive nephrotic syndrome: an open-label pilot randomized controlled trial
Background Rituximab and tacrolimus are therapies reserved for patients with frequently
relapsing or steroid-dependent nephrotic syndrome who have failed conventional steroid …
relapsing or steroid-dependent nephrotic syndrome who have failed conventional steroid …
Efficacy of rituximab versus tacrolimus in difficult-to-treat steroid-sensitive nephrotic syndrome: an open-label pilot randomized controlled trial.
G Mathew, A Sinha, A Ahmed, N Grewal… - Pediatric …, 2022 - go.gale.com
Background Rituximab and tacrolimus are therapies reserved for patients with frequently
relapsing or steroid-dependent nephrotic syndrome who have failed conventional steroid …
relapsing or steroid-dependent nephrotic syndrome who have failed conventional steroid …
Efficacy of rituximab versus tacrolimus in difficult-to-treat steroid-sensitive nephrotic syndrome: an open-label pilot randomized controlled trial.
G Mathew, A Sinha, A Ahmed, N Grewal… - Pediatric …, 2022 - search.ebscohost.com
Background: Rituximab and tacrolimus are therapies reserved for patients with frequently
relapsing or steroid-dependent nephrotic syndrome who have failed conventional steroid …
relapsing or steroid-dependent nephrotic syndrome who have failed conventional steroid …
[PDF][PDF] Efficacy of rituximab versus tacrolimus in difficult‑to‑treat steroid‑sensitive nephrotic syndrome: an open‑label pilot randomized controlled trial
G Mathew, A Sinha, A Ahmed, N Grewal, P Khandelwal… - researchgate.net
Background Rituximab and tacrolimus are therapies reserved for patients with frequently
relapsing or steroid-dependent nephrotic syndrome who have failed conventional steroid …
relapsing or steroid-dependent nephrotic syndrome who have failed conventional steroid …
Efficacy of rituximab versus tacrolimus in difficult-to-treat steroid-sensitive nephrotic syndrome: an open-label pilot randomized controlled trial.
G Mathew, A Sinha, A Ahmed, N Grewal… - Pediatric Nephrology …, 2022 - europepmc.org
Background Rituximab and tacrolimus are therapies reserved for patients with frequently
relapsing or steroid-dependent nephrotic syndrome who have failed conventional steroid …
relapsing or steroid-dependent nephrotic syndrome who have failed conventional steroid …
Efficacy of rituximab versus tacrolimus in difficult-to-treat steroid-sensitive nephrotic syndrome: an open-label pilot randomized controlled trial
G Mathew, A Sinha, A Ahmed, N Grewal, P Khandelwal… - 2022 - pubmed.ncbi.nlm.nih.gov
Background Rituximab and tacrolimus are therapies reserved for patients with frequently
relapsing or steroid-dependent nephrotic syndrome who have failed conventional steroid …
relapsing or steroid-dependent nephrotic syndrome who have failed conventional steroid …
[HTML][HTML] Efficacy of rituximab versus tacrolimus in difficult-to-treat steroid-sensitive nephrotic syndrome: an open-label pilot randomized controlled trial
G Mathew, A Sinha, A Ahmed, N Grewal… - Pediatric Nephrology …, 2022 - ncbi.nlm.nih.gov
Background Rituximab and tacrolimus are therapies reserved for patients with frequently
relapsing or steroid-dependent nephrotic syndrome who have failed conventional steroid …
relapsing or steroid-dependent nephrotic syndrome who have failed conventional steroid …
Efficacy of rituximab versus tacrolimus in difficult-to-treat steroid-sensitive nephrotic syndrome: an open-label pilot randomized controlled trial.
G Mathew, A Sinha, A Ahmed, N Grewal… - Pediatric Nephrology …, 2022 - europepmc.org
Background Rituximab and tacrolimus are therapies reserved for patients with frequently
relapsing or steroid-dependent nephrotic syndrome who have failed conventional steroid …
relapsing or steroid-dependent nephrotic syndrome who have failed conventional steroid …